Paul J. Hastings net worth and biography

Paul Hastings Biography and Net Worth

CEO of Nkarta
Mr. Hastings was appointed Chief Executive Officer of Nkarta in February 2018. Mr. Hastings was recently the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.

He is currently Lead Independent Director of Pacira Biosciences, Inc., and Director at ViaCyte. He also serves as Chair of the Biotechnology Innovation Organization (BIO). Mr. Hastings was recently the Chairman of the Board of Proteon Therapeutics, was on the Board of Directors of Relypsa, Inc. (acquired by Galenica), was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010) and served on the board of ViaCell (sold to Perkin-Elmer in 2007).

Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

What is Paul J. Hastings' net worth?

The estimated net worth of Paul J. Hastings is at least $3.30 million as of September 28th, 2022. Mr. Hastings owns 250,959 shares of Nkarta stock worth more than $3,302,620 as of October 2nd. This net worth estimate does not reflect any other investments that Mr. Hastings may own. Additionally, Mr. Hastings receives a salary of $902,220.00 as CEO at Nkarta. Learn More about Paul J. Hastings' net worth.

How old is Paul J. Hastings?

Mr. Hastings is currently 62 years old. There are 4 older executives and no younger executives at Nkarta. Learn More on Paul J. Hastings' age.

What is Paul J. Hastings' salary?

As the CEO of Nkarta, Inc., Mr. Hastings earned a total compensation package of $6,775,031.00 in 2021. Mr. Hastings earned a salary of $576,466.00, options awards of $5,872,808.00, non-equity compensation of $317,057.00, and other compensation of $8,700.00. Learn More on Paul J. Hastings' salary.

How do I contact Paul J. Hastings?

The corporate mailing address for Mr. Hastings and other Nkarta executives is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. Nkarta can also be reached via phone at 415-582-4923 and via email at [email protected] Learn More on Paul J. Hastings' contact information.

Has Paul J. Hastings been buying or selling shares of Nkarta?

Paul J. Hastings has not been actively trading shares of Nkarta during the past quarter. Most recently, Paul J. Hastings sold 23,376 shares of the business's stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $13.03, for a transaction totalling $304,589.28. Following the completion of the sale, the chief executive officer now directly owns 250,959 shares of the company's stock, valued at $3,269,995.77. Learn More on Paul J. Hastings' trading history.

Who are Nkarta's active insiders?

Nkarta's insider roster includes Ralph Brandenberger (Insider), Paul Hastings (CEO), Nadir Mahmood (Insider), and Kanya Rajangam (Insider). Learn More on Nkarta's active insiders.

Are insiders buying or selling shares of Nkarta?

During the last year, Nkarta insiders bought shares 2 times. They purchased a total of 3,533,333 shares worth more than $52,999,995.00. During the last year, insiders at the sold shares 7 times. They sold a total of 57,375 shares worth more than $818,825.57. The most recent insider tranaction occured on September, 28th when CEO Paul J Hastings sold 23,376 shares worth more than $304,589.28. Insiders at Nkarta own 5.6 % of the company. Learn More about insider trades at Nkarta.

Information on this page was last updated on 9/28/2022.

Paul J. Hastings Insider Trading History at Nkarta

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/28/2022Sell23,376$13.03$304,589.28250,959View SEC Filing Icon  
9/21/2022Sell6,126$13.01$79,699.26274,335View SEC Filing Icon  
9/29/2021Sell8,500$27.18$231,030.00View SEC Filing Icon  
6/21/2021Sell8,500$26.61$226,185.00View SEC Filing Icon  
3/30/2021Sell17,000$30.74$522,580.00View SEC Filing Icon  
See Full Table

Paul J. Hastings Buying and Selling Activity at Nkarta

This chart shows Paul J Hastings's buying and selling at Nkarta by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nkarta Company Overview

Nkarta logo
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $13.16
Low: $12.58
High: $13.66

50 Day Range

MA: $14.42
Low: $12.27
High: $18.39

2 Week Range

Now: $13.16
Low: $7.55
High: $27.82

Volume

261,748 shs

Average Volume

448,365 shs

Market Capitalization

$640.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07